Rheumatology
Conference Coverage
Registry data ‘reassure’ on biologics’ heart attack risk in rheumatoid arthritis
There is no difference in the risk of myocardial infarction with interleukin-6 (IL-6) vs. anti–tumor necrosis factor (TNF) therapy for rheumatoid...
Conference Coverage
Metformin linked to reduced osteoarthritis risk
Though the findings were in observational studies, one of which did not reach significance, the results line up with the findings of other...
From the Journals
Antiphospholipid antibodies linked to future CV events
The study raises the possibility of one day treating the immune system in some individuals for the prevention and treatment of cardiovascular...
Conference Coverage
Childhood lupus severity linked to social determinants of health
Social determinants of health were linked to lupus disease severity in children, but it will take more than awareness among doctors to address the...
Conference Coverage
Metabolic syndrome linked to knee pain in middle adulthood
Metabolic syndrome that develops in middle age had a greater association with osteoarthritis knee symptoms and pain than metabolic syndrome that...
Feature
New coalition aims to revolutionize stalled lupus research
Public-private consortium plans to develop new approaches to clinical studies.
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
Conference Coverage
Osteoarthritis adjunctive therapies offer negligible added benefit to exercise
Interventions such as electrophysical stimulation and acupuncture don’t appear to offer much benefit in reducing pain or improving physical...
Conference Coverage
Antidepressants benefit some patients with osteoarthritis pain
Although some patients benefit from antidepressants for osteoarthritis pain, it’s difficult to know which patients will benefit and which will be...
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Latest News
Anifrolumab shows promise in refractory discoid lupus erythematosus
Anifrolumab improved symptoms and activity of DLE within 2 months in a study of eight women.